Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

BACKGROUND: Clinical studies have shown that integrase strand transfer inhibitors can be used to treat HIV-1 infection. Although the first-generation integrase inhibitors are susceptible to the emergence of resistance mutations that impair their efficacy in therapy, such resistance has not been iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesplède, Thibault, Quashie, Peter K, Osman, Nathan, Han, Yingshan, Singhroy, Diane N, Lie, Yolanda, Petropoulos, Christos J, Huang, Wei, Wainberg, Mark A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598531/
https://www.ncbi.nlm.nih.gov/pubmed/23432922
http://dx.doi.org/10.1186/1742-4690-10-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598531/
https://www.ncbi.nlm.nih.gov/pubmed/23432922
http://dx.doi.org/10.1186/1742-4690-10-22

Ejemplares similares